Saturday, October 17, 2026 from 3:30 p.m. to 5:00 p.m. MDT at Salt Palace Convention Center - Ballroom I
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-26-149-L01-PActivity Type: A Knowledge-Based ActivityMyasthenia gravis (MG) is a complex autoimmune neuromuscular disorder that demands nuanced, multidisciplinary management. This 90-minute session will equip clinical pharmacists with the knowledge and tools to optimize care across the therapeutic spectrum - from foundational principles to cutting-edge innovations. The program features three expert-led segments, including background and diagnosis, current therapies and pharmacist roles, and emerging therapies and future directions.
Interactive Q&A segments will foster discussion on real-world challenges and opportunities for clinical pharmacists to optimize MG therapy. Attendees will leave with actionable strategies to enhance patient outcomes and stay ahead of evolving treatment paradigms.
Learning Objectives1. Describe the pathophysiology and symptomatology of myasthenia gravis and its subtypes.
2. Review treatment options for myasthenia gravis, including cholinesterase inhibitors, immunosuppressants, and rapid-response modalities.
3. Discuss current standard of care for selection of agents for acute myasthenia gravis management.
4. Discuss current standard of care for selection of agents for chronic myasthenia gravis management.
5. Explain how novel agents are utilized in the management of myasthenia gravis to create an individualized patient treatment plan.
6. Describe opportunities to optimize patient access to prescribed therapies, including considerations for formulary integration and patient-assistance plans.
Winding Up the Story: A Historical Look at MG Pathophysiology3:30 p.m. |
Right on Time: Current Therapeutic Strategies for Myasthenia Gravis3:55 p.m. to 4:20 p.m. |
Fast Forward: Next-Generation Therapies for MG4:20 p.m. to 4:45 p.m. |
Panel Q&A Discussion4:45 p.m. to 5:00 p.m. |